Prapela

Neonatal abstinence syndrome (NAS) is a high-priority, pediatric health problem tragically impacting newborns and disproportionately poor families. This year alone an estimated 50,000 NAS infants will be treated at a cost of more than $3 billion. Prapela is developing a next gen baby box with technology proven to help drug-exposed infants. The clinically-validated technology, Stochastic Vibro-tactile Stimulation (SVS), has been developed at Harvard’s Wyss Institute in collaboration with physicians and researchers from the University of Massachusetts Medical School, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. This low-cost, non-pharmacological, non-invasive solution is designed to be used in the hospital and taken home. Although initially focused on NAS, Prapela intends to use its SVS technology to help achieve better respiratory outcomes with premature infants, support newborns with heart defects, and soothe babies with colic and other sleep issues. Learn more.